rhTPO与rhIL-11治疗实体瘤化疗后化疗相关性血小板减少症的疗效及安全性对比  

Comparison of efficacy and safety of rhTPO and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia after chemotherapy in solid tumors

作　　者：张玄 ZHANG Xuan(Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,China)

机构地区：[1]徐州医科大学附属医院,221000

出　　处：《中国现代药物应用》2023年第6期14-17,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨重组人血小板生成素(rhTPO)与重组人白细胞介素-11(rhIL-11)治疗实体瘤化疗后化疗相关性血小板减少症(CIT)的疗效及安全性。方法60例实体瘤化疗后CIT患者,按随机数字表法分为观察组和对照组,各30例。对照组给予rhIL-11治疗,观察组给予rhTPO治疗。每2天检测患者血常规,若血小板(PLT)升高幅度>50×10^(9)/L或升高至100×10^(9)/L即可停止给药。比较两组临床疗效,2级以上血小板减少的持续时间、血小板恢复正常所需时间、血小板输注率、血小板输注治疗成本,不同时间点血小板变化,生活质量评分,不良反应发生情况。结果治疗后,观察组临床总有效率96.67%高于对照组的73.33%(P<0.05)。观察组2级以上血小板减少的持续时间(4.24±1.13)d、血小板恢复正常所需时间(8.72±1.76)d均短于对照组的(6.16±1.52)、(9.77±2.11)d,血小板输注率6.67%、血小板输注治疗成本(1287.65±93.13)元均低于对照组的26.67%、(3052.43±95.29)元(P<0.05)。与治疗前比较,治疗3、5、7、9、11 d后,两组血小板呈先降低后升高的趋势,组内不同时间点比较,差异具有统计学意义(P<0.05);且观察组治疗3、5 d后的血小板均高于对照组(P<0.05)。治疗后,观察组功能维度评分(71.55±11.41)分高于对照组的(53.68±11.26)分(P<0.05)。与对照组治疗期间不良反应发生率56.67%进行比较,观察组的10.00%更低,差异具有统计学意义(P<0.05)。结论rhTPO治疗实体瘤化疗后CIT可有效促进患者血小板恢复正常,降低血小板输注率和输注成本,改善血小板水平,促进功能快速恢复,疗效显著且安全性较高。Objective To discuss the efficacy and safety of recombinant human thrombopoietin(rhTPO)and recombinant human interleukin-11(rhIL-11)in the treatment of chemotherapy-induced thrombocytopenia(CIT)after chemotherapy in solid tumors.Methods A total of 60 patients with CIT after chemotherapy in solid tumors were divided into observation group and control group according to the random numerical table,with 30 cases in each group.The control group was treated with rhIL-11,and the observation group was treated with rhTPO.Patients'blood routine was tested every 2 days,and the drug administration could be stopped if the platelet(PLT)increased by>50×10^(9)/L or increased to 100×10^(9)/L.Both groups were compared in terms of clinical efficacy,duration of grade 2 or above thrombocytopenia,time required for platelets to return to normal,platelet infusion rate,cost of platelet infusion,changes in platelets at different time points,quality of life scores,and occurrence of adverse reactions.Results After treatment,the total clinical efficiency was 96.67%in the observation group,which was higher than that of 73.33%in the control group(P<0.05).The duration of grade 2 or above thrombocytopenia in the observation group was(4.24±1.13)d and the time required for platelets to return to normal was(8.72±1.76)d,which were shorter than those of(6.16±1.52)and(9.77±2.11)d in the control group;the platelet infusion rate of 6.67%and the cost of platelet infusion of(1287.65±93.13)yuan in the observation group were lower than those of 26.67%and(3052.43±95.29)yuan in the control group(P<0.05).After 3,5,7,9 and 11 d of treatment,the platelets in the two groups showed a trend of decreasing and then increasing compared with those before treatment,and the difference was statistically significant at different time points within the group(P<0.05).The platelets after 3 and 5 d of treatment in the observation group were higher than those in the control group(P<0.05).After treatment,the functional dimension score was(53.68±11.26)points in the obser

关 键 词：实体瘤 化疗相关性血小板减少症 重组人白细胞介素-11 重组人血小板生成素 

分 类 号：R730.53[医药卫生—肿瘤] R558.2[医药卫生—临床医学]